Sol-Gel Technologies Return on Investment 2016-2023 | SLGL
Current and historical return on investment (ROI) values for Sol-Gel Technologies (SLGL) over the last 10 years.
| Sol-Gel Technologies ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2023-12-31 |
$-0.03B |
|
inf% |
| 2023-09-30 |
$-0.03B |
|
inf% |
| 2023-06-30 |
$-0.03B |
|
inf% |
| 2023-03-31 |
$-0.02B |
|
inf% |
| 2022-12-31 |
$-0.02B |
|
inf% |
| 2022-09-30 |
$0.00B |
|
inf% |
| 2022-06-30 |
$0.01B |
|
inf% |
| 2022-03-31 |
$0.00B |
|
inf% |
| 2021-12-31 |
$0.00B |
|
inf% |
| 2021-09-30 |
$-0.02B |
|
inf% |
| 2021-06-30 |
$-0.03B |
|
inf% |
| 2021-03-31 |
$-0.03B |
|
inf% |
| 2020-12-31 |
$-0.03B |
|
inf% |
| 2020-09-30 |
$-0.03B |
|
inf% |
| 2020-06-30 |
$-0.03B |
|
inf% |
| 2020-03-31 |
$-0.03B |
|
inf% |
| 2019-12-31 |
$-0.03B |
|
inf% |
| 2019-09-30 |
$-0.03B |
|
inf% |
| 2019-06-30 |
$-0.03B |
|
inf% |
| 2019-03-31 |
$-0.03B |
|
inf% |
| 2018-12-31 |
$-0.03B |
|
inf% |
| 2018-03-31 |
$-0.01B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.023B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
